GnRH agonist plus letrozole may improve live birth rates in patients with implantation failure

  • Steiner N & al.
  • Fertil Steril
  • 24 May 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Treatment with gonadotropin-releasing hormone (GnRH) agonist plus the aromatase inhibitor letrozole (Femara) is associated with increased live birth rates compared with GnRH alone or no treatment in patients with idiopathic recurrent implantation failure.

Why this matters

  • Study suggests that treating undiagnosed endometriosis can improve in vitro fertilization (IVF) outcomes.

Key results

  • GnRH agonist plus letrozole was associated with a higher clinical pregnancy rate (63%) compared with GnRH agonist alone (42%) or no treatment (40%) (P<.0001 for both>
  • GnRH agonist plus letrozole was associated with a higher live birth rate (56%) compared with GnRH agonist alone (36%) or no treatment (34%) (P<.0001 for both>

Study design

  • 523 infertile participants undergoing a third blastocyst transfer after 2 failed blastocyst transfers, 176 who received GnRH agonist and letrozole, 143 who received GnRH agonist alone, and 204 who did not receive treatment were analyzed for pregnancy outcomes.
  • Funding: None disclosed.

Limitations

  • Retrospective study.
  • Unclear presentation of multivariate analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit